PAI
AEGR

Palo Alto Investors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Palo Alto Investors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-49,040
Closed -$3.11M – 35
2013
Q2 		$3.11M Buy
+49,040
New +$2.6M 0.37% 24

Other funds holding AEGR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Palo Alto Investors's AEGR Position: Q3 2013 in Review

Palo Alto Investors sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2013, closing a stake of 49,040 shares — an estimated $3.11M sold.

Palo Alto Investors first reported a position in AEGR in Q2 2013 and held it in 1 quarter. The position peaked at $3.11M in Q2 2013. 154 funds tracked by Wall St. Rank hold AEGR as of Q3 2013.

  • Palo Alto Investors reported no remaining Aegerion Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Palo Alto Investors sold 49,040 Aegerion Pharmaceuticals shares in Q3 2013, an estimated $3.11M.
  • Palo Alto Investors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Palo Alto Investors's Aegerion Pharmaceuticals position peaked at $3.11M in Q2 2013.
  • 154 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2013.

Based on Palo Alto Investors's 13F filing for Q3 2013, filed 13 Nov 2013.